133 active not recruiting. 133 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 133 | Active not recruiting 133 |
| Phase 2 | 12 | Active not recruiting 12 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer Trilaciclib, Trilaciclib Placebo, Etoposide Injection - Myelosuppression | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 106 | 2026-06-17 | 2026-10-19 |
| Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) QL2107, Keytruda® - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Qilu Pharmaceutical Co., Ltd. | 146 | 2025-11-21 | 2026-10-22 |
| A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC SHR-A2009 ; Aumolertinib, Aumolertinib - Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 582 | 2025-10-30 | 2026-09-25 |
| Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. Durvalumab - Small Cell Lung Carcinoma | Phase 3 | Active not recruiting | AstraZeneca | 71 | 2025-09-15 | 2026-10-26 |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) Tarlatamab, Durvalumab, Carboplatin - Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 350 | 2025-08-18 | 2026-09-08 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 630 | 2025-08-07 | 2026-09-21 |
| Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms ETOPOSIDE - Usual, ETOPOSIDE - Study - Small Cell Lung Cancer | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 600 | 2025-07-16 | 2026-08-27 |
| Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） Radiotherapy or Surgery, Standard Medical Therapy - OligoProgressive Metastatic Disease, Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Active not recruiting | Shanghai Chest Hospital | 97 | 2025-06-03 | 2025-07-22 |
| Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed - Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Active not recruiting | Immutep S.A.S. | 756 | 2025-03-21 | 2026-03-18 |
| A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302) YL201, topotecan hydrochloride for injection - Small Cell Lung Cancer | Phase 3 | Active not recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 438 | 2024-12-17 | 2026-09-15 |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 3 | Active not recruiting | NRG Oncology | 274 | 2024-12-12 | 2026-09-14 |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer Surgical Procedure, Cisplatin, Carboplatin - Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 37 | 2024-12-11 | 2026-09-02 |
| A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC SHR-A2009 monotherapy, platinum-based dual-agent chemotherapy - Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 498 | 2024-11-29 | 2026-03-19 |
| A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer SKB264, Osimertinib - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 420 | 2024-11-27 | 2026-07-10 |
| Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) Acasunlimab, Pembrolizumab, Docetaxel - PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Phase 3 | Active not recruiting | Genmab | 191 | 2024-11-25 | 2026-11-03 |
| A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab - Lung Cancer, Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 67 | 2024-11-21 | 2026-07-21 |
| A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer SKB264, Pembrolizumab, pemetrexed - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 432 | 2024-10-30 | 2026-07-08 |
| A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features Datopotamab Deruxtecan, Rilvegostomig, Carboplatin - Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | AstraZeneca | 25 | 2024-10-15 | 2026-09-23 |
| A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Dato-DXd, Osimertinib, Pemetrexed - Metastatic Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | AstraZeneca | 768 | 2024-10-04 | 2026-10-15 |
| A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Divarasib, Sotorasib, Adagrasib - Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 338 | 2024-09-23 | 2026-09-16 |
Showing 20 of 133. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (105) · Lung Neoplasms (29) · Small Cell Lung Carcinoma (18) · Neoplasm Metastasis (5) · Carcinoma (4) · Lung Diseases (4) · Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Adenocarcinoma of Lung (2) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Renal Cell (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Respiratory Tract Neoplasms (2)
Neoplasms by Site (132) · Respiratory Tract Diseases (132) · Neoplasms (131) · Respiratory Tract Neoplasms (131) · Lung Diseases (128) · Bronchial Neoplasms (122) · Carcinoma, Bronchogenic (121) · Lung Neoplasms (103) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Pathological Conditions, Signs and Symptoms (7) · Carcinoma (5) · Pathologic Processes (5) · Adenocarcinoma (4)
Carboplatin (47) · Pemetrexed (38) · Cisplatin (37) · pembrolizumab (34) · durvalumab (19) · Paclitaxel (17) · Docetaxel (15) · Etoposide (12) · osimertinib (11) · Magnetic Resonance Spectroscopy (8) · Crizotinib (7) · Gemcitabine (7) · Nivolumab (7) · Specimen Handling (7) · atezolizumab (7)
AstraZeneca (22) · Merck Sharp & Dohme LLC (11) · National Cancer Institute (NCI) (8) · Hoffmann-La Roche (7) · Amgen (5) · Eli Lilly and Company (4) · Janssen Research & Development, LLC (4) · Sichuan Baili Pharmaceutical Co., Ltd. (4) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (4) · Daiichi Sankyo (3) · SWOG Cancer Research Network (3) · Bristol-Myers Squibb (2) · Gilead Sciences (2) · GlaxoSmithKline (2) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (2)
United States (94) · China (85) · Spain (73) · Germany (65) · Japan (65) · Italy (64) · South Korea (64) · France (63) · Poland (63) · Canada (62) · Turkey (Türkiye) (62) · Brazil (57) · Taiwan (55) · United Kingdom (52) · Belgium (48)
Haiyi Jiang, M.D. (2) · Li Zhang (2) · Shun Lu, MD (2) · Yilong Wu, MD (2)
PMID 40311309, PMID 26432508, PMID 26837474, PMID 27894601, PMID 28492898, PMID 28501139, PMID 29074098, PMID 29317191, PMID 31590988, PMID 31591063, PMID 31948903, PMID 32271377, PMID 32615102, PMID 33150799, PMID 33194700, PMID 33199228, PMID 33207094, PMID 33285097, PMID 33415649, PMID 33558193, PMID 33610453, PMID 33661301, PMID 33775558, PMID 34156285, PMID 34278827, PMID 34473194, PMID 34543864, PMID 34585621, PMID 34795131, PMID 34810130, PMID 34911336, PMID 34928484, PMID 35135810, PMID 35369607, PMID 35378489, PMID 35605188, PMID 35613997, PMID 35613998, PMID 35618629, PMID 35841410, PMID 35858590, PMID 35950566, PMID 35995953, PMID 36006678, PMID 36535300, PMID 37249038, PMID 37272513, PMID 37295609, PMID 37329423, PMID 37390764
2023 (30), 2019 (7), 2018 (6), U10CA180820 (5), U10CA180888 (4), 2017 (3), U10CA180868 (3), U10CA180821 (2), U10CA180830 (2), 2014 (1), 2015 (1), 2016 (1), 2025 (1), R01CA249501 (1), U10CA021115 (1)